Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [¹⁴C]-LY3502970 in Healthy Males
NCT04680767Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Eli Lilly and Company. Primary endpoints: Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Mar 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04680767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680767.